Health Catalyst, Inc
3.3400-0.04 (-1.18%)
Oct 29, 4:00:01 PM EDT · NasdaqGS · HCAT · USD
Key Stats
Market Cap
235.05MP/E (TTM)
-Basic EPS (TTM)
-1.51Dividend Yield
0%Recent Filings
8-K
Albert named President and COO
Health Catalyst appointed Benjamin Albert as President and Chief Operating Officer effective September 16, 2025, to steer daily operations amid CEO Dan Burton's planned retirement in June 2026. Albert, who led the acquired Upfront Healthcare Services unit since January 2025, steps in with a $475,000 salary, 75% target bonus, 467,000 RSUs vesting over three years, and 233,000 PRSUs tied to TSR, EBITDA margin, and revenue growth. Dan LeSueur exits the COO role September 15, 2025, without disagreement, transitioning to advisory duties. This shift bolsters continuity while risks from leadership changes persist.
10-Q
Q2 FY2025 results
Health Catalyst's Q2 FY2025 results, ended June 30, 2025, showed revenue growth, though specific figures await full disclosure in the filing. The company maintained its accelerated filer status, with 70,373,625 common shares outstanding as of July 31, 2025. No material M&A, debt details, or regulatory updates appeared in the provided sections. Non-GAAP metrics not disclosed in the 10-Q. Balance sheet and cash flow statements indicate steady operations. Investors face risks from intense competition in healthcare analytics.
8-K
Q2 earnings and CEO retirement
Health Catalyst reported Q2 2025 revenue of $80.7 million, up 6% year-over-year, with Adjusted EBITDA hitting $9.3 million—a 24% jump—despite a $28.8 million goodwill impairment driving net loss to $41.0 million. CEO Dan Burton announced his retirement effective June 30, 2026, after 15 years, with no successor named yet; the board expanded to eight directors, appointing Justin Spencer, ex-CFO of Vocera Communications, effective September 1. Restructuring cuts 9% of workforce to boost profitability by over $40 million annually. Transition risks loom amid macro headwinds.
8-K
Annual meeting results approved
Health Catalyst's stockholders overwhelmingly elected Duncan Gallagher and Dr. Jill Hoggard Green as Class III directors for three-year terms at the July 9, 2025 annual meeting, with Gallagher facing notable withheld votes. They ratified Ernst & Young as auditors and approved executive compensation on advisory votes. Stockholders also backed declassifying the board, signaling push for annual director elections. Votes tallied from 53 million shares present.
10-Q
Q1 FY2025 results
Health Catalyst's Q1 2025 results show revenue up 18.5% year-over-year to $79.0 million, driven by steady growth in technology and professional services segments, though gross margin dipped to 47.2% from 48.1% amid higher costs. Operating loss narrowed to $15.2 million from $20.4 million last year, while net loss improved to $18.7 million, with the gap largely due to stock-based compensation and interest expenses. Diluted EPS came in at ($0.27), aligning with 69.4 million weighted-average shares. Cash from operations reached $12.5 million, yielding free cash flow of $8.9 million after $3.6 million in capex. Balance sheet stays solid with $147.2 million in cash and equivalents, no revolver draw on the $75 million facility. No major M&A or regulatory updates noted. Competition from larger tech players remains a key risk.
IPO
Employees
Sector
Industry
CCLD
CareCloud, Inc.
3.02-0.02
DH
Definitive Healthcare Corp.
2.77-0.17
GEHC
GE HealthCare Technologies Inc.
77.38-2.02
HCTI
Healthcare Triangle, Inc.
3.01+0.13
HIT
Health In Tech, Inc.
2.78-0.07
HNGE
Hinge Health, Inc.
49.60-1.37
HQY
HealthEquity, Inc.
94.44-0.71
HYDTF
Hydreight Technologies Inc
3.28-0.09
NRC
National Research Corporation
13.45+0.20
TBRG
TruBridge, Inc.
19.49-0.03